The drug market for opioid induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) and used off-label. However, many patients turn to OTC therapies, keeping drug-treatment rates low. As a result, recently approved therapies such as Motegrity and Zelnorm have had difficulty gaining market share. More-established therapies such as Linzess, Amitiza, and Movantik continue to secure use in both newly diagnosed and recently treated patients. Persistency and compliance rates are relatively low in this market compared with other indications, highlighting the importance of securing early use.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Allergan / Ironwood, Synergy Pharma, Takeda / Mallinckrodt, Alfasigma, Takeda, Ardelyx, AstraZeneca / Daiichi Sankyo
Key drugs: Zelnorm, Motegrity, Ibsrela, Relistor, Symproic, Movantik, naloxone, stimulant laxatives, osmotic laxatives, dietary fiber supplements